moxifloxacin has been researched along with Experimental Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Askenasy, N; Fabian, I; Halperin, D; Reuveni, D; Shalit, I; Tsarfaty, G | 1 |
| Enzmann, HG; Iatropoulos, MJ; Jeffrey, AM; Schlueter, G; von Keutz, E; Williams, GM | 1 |
2 other study(ies) available for moxifloxacin and Experimental Neoplasms
| Article | Year |
|---|---|
Moxifloxacin increases anti-tumor and anti-angiogenic activity of irinotecan in human xenograft tumors.
Topics: Angiogenesis Inhibitors; Animals; Anti-Infective Agents; Antineoplastic Agents; Aza Compounds; Camptothecin; Cell Proliferation; Drug Synergism; Female; Fluoroquinolones; Humans; Interleukin-8; Irinotecan; Mice; Mice, SCID; Moxifloxacin; Neoplasms, Experimental; Platelet Endothelial Cell Adhesion Molecule-1; Quinolines; Ultrasonography, Doppler; Xenograft Model Antitumor Assays | 2010 |
Assessment of chronic toxicity and carcinogenicity in an accelerated cancer bioassay in rats of moxifloxacin, a quinolone antibiotic.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Aza Compounds; Body Weight; Carcinogenicity Tests; Carcinogens; Cocarcinogenesis; Female; Fluoroquinolones; Male; Moxifloxacin; Neoplasms, Experimental; Organ Size; Quinolines; Rats; Rats, Wistar; Time Factors | 2001 |